Hilde Carlier

1.7k total citations
26 papers, 644 citations indexed

About

Hilde Carlier is a scholar working on Immunology, Rheumatology and Hematology. According to data from OpenAlex, Hilde Carlier has authored 26 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 15 papers in Rheumatology and 7 papers in Hematology. Recurrent topics in Hilde Carlier's work include Psoriasis: Treatment and Pathogenesis (12 papers), Spondyloarthritis Studies and Treatments (12 papers) and Rheumatoid Arthritis Research and Therapies (11 papers). Hilde Carlier is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (12 papers), Spondyloarthritis Studies and Treatments (12 papers) and Rheumatoid Arthritis Research and Therapies (11 papers). Hilde Carlier collaborates with scholars based in United States, Canada and Netherlands. Hilde Carlier's co-authors include Désirée van der Heijde, Fangyi Zhao, John D. Reveille, Masato Okada, Philip J. Mease, Catherine L Shuler, Mitsumasa Kishimoto, Xiaoqi Li, Suchitrita S. Rathmann and Olivier Bénichou and has published in prestigious journals such as Gastroenterology, The Journal of Infectious Diseases and Annals of the Rheumatic Diseases.

In The Last Decade

Hilde Carlier

26 papers receiving 638 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hilde Carlier United States	12	390	380	157	86	84	26	644
Dilek Arikan United States	11	144 0.4×	100 0.3×	60 0.4×	93 1.1×	90 1.1×	25	417
Richard Hagan Ireland	10	249 0.6×	83 0.2×	32 0.2×	23 0.3×	188 2.2×	17	532
Nurit Vardinon Israel	10	118 0.3×	163 0.4×	31 0.2×	81 0.9×	31 0.4×	14	395
Todd Fox Switzerland	12	506 1.3×	190 0.5×	147 0.9×	84 1.0×	109 1.3×	20	672
S Manners Canada	3	153 0.4×	137 0.4×	66 0.4×	325 3.8×	258 3.1×	5	609
John L. Fahey United States	9	97 0.2×	38 0.1×	177 1.1×	177 2.1×	176 2.1×	9	630
Carmen Hidalgo Spain	7	113 0.3×	135 0.4×	17 0.1×	34 0.4×	51 0.6×	18	301
Malaviya An India	10	73 0.2×	112 0.3×	36 0.2×	68 0.8×	82 1.0×	88	345
Juan M. Cubillos-Angulo Brazil	12	69 0.2×	56 0.1×	28 0.2×	104 1.2×	103 1.2×	25	306
J.M. Hernánz Spain	13	249 0.6×	76 0.2×	21 0.1×	57 0.7×	78 0.9×	28	445

Countries citing papers authored by Hilde Carlier

Since Specialization

Citations

This map shows the geographic impact of Hilde Carlier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilde Carlier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilde Carlier more than expected).

Fields of papers citing papers by Hilde Carlier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilde Carlier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilde Carlier. The network helps show where Hilde Carlier may publish in the future.

Co-authorship network of co-authors of Hilde Carlier

This figure shows the co-authorship network connecting the top 25 collaborators of Hilde Carlier. A scholar is included among the top collaborators of Hilde Carlier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilde Carlier. Hilde Carlier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Macey, Jake, H.L.J. Makin, Katie Mellor, et al.. (2024). P720 Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn disease. Journal of Crohn s and Colitis. 18(Supplement_1). i1343–i1344. 3 indexed citations

Sands, Bruce E., Silvio Danese, Minhu Chen, et al.. (2024). Su1801 PRIMARY EFFICACY AND SAFETY OF MIRIKIZUMAB IN MODERATE TO SEVERE CROHN'S DISEASE: RESULTS OF THE TREAT-THROUGH VIVID 1 STUDY. Gastroenterology. 166(5). S–820. 1 indexed citations

Ferrante, Marc, Silvio Danese, M Chen, et al.. (2024). OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study. Journal of Crohn s and Colitis. 18(Supplement_1). i7–i9. 11 indexed citations

Magro, Fernando, Marijana Protić, Gert De Hertogh, et al.. (2023). Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial. Clinical Gastroenterology and Hepatology. 22(9). 1878–1888.e10. 7 indexed citations

Kiltz, Uta, Désirée van der Heijde, Annelies Boonen, et al.. (2023). Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials. The Journal of Rheumatology. 50(6). 754–762. 2 indexed citations

Uzzan, Mathieu, Yoram Bouhnik, María T. Abreu, et al.. (2023). Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. Journal of Crohn s and Colitis. 17(7). 1066–1078. 26 indexed citations

Maksymowych, Walter P., Xenofon Baraliakos, R. Lambert, et al.. (2022). Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis. The Lancet Rheumatology. 4(9). e626–e634. 15 indexed citations

Regueiro, Miguel, Monika Fischer, David T. Rubin, et al.. (2022). S834 Improvement in Fatigue With Mirikizumab Therapy Is Associated With Clinical Remission and Pain Improvements but Not With Endoscopic Response in Patients With Moderately-to-Severely Active Crohn’s Disease. The American Journal of Gastroenterology. 117(10S). e602–e603. 1 indexed citations

Heijde, Désirée van der, Mikkel Østergaard, John D. Reveille, et al.. (2021). Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years. The Journal of Rheumatology. 49(3). 265–273. 25 indexed citations

10.

Landewé, Robert, Lianne S. Gensler, Denis Poddubnyy, et al.. (2021). Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Annals of the Rheumatic Diseases. 80(8). 1022–1030. 19 indexed citations

11.

Kiltz, Uta, Désirée van der Heijde, Filip Van den Bosch, et al.. (2020). Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. The Journal of Rheumatology. 48(2). 188–197. 6 indexed citations

12.

Dougados, Maxime, James Cheng‐Chung Wei, Robert Landewé, et al.. (2019). Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Annals of the Rheumatic Diseases. 79(2). 176–185. 86 indexed citations

13.

Deodhar, Atul, Denis Poddubnyy, César Pacheco‐Tena, et al.. (2018). Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis & Rheumatology. 71(4). 599–611. 149 indexed citations

14.

Mease, Philip J., Masato Okada, Mitsumasa Kishimoto, et al.. (2017). 397 Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis. Journal of Investigative Dermatology. 137(10). S260–S260. 7 indexed citations

15.

Heijde, Désirée van der, Dafna D. Gladman, Mitsumasa Kishimoto, et al.. (2017). Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). The Journal of Rheumatology. 45(3). 367–377. 96 indexed citations

16.

Kimball, Alexa B., Thomas A. Luger, Alice B. Gottlieb, et al.. (2016). Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. Journal of the American Academy of Dermatology. 75(6). 1156–1161. 36 indexed citations

17.

Genovese, Mark C., Daniel Braun, J. Erickson, et al.. (2015). Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis. The Journal of Rheumatology. 43(2). 289–297. 30 indexed citations

18.

Maat, Monique M. R. de, Ron A. A. Mathôt, Agnes I. Veldkamp, et al.. (2002). HEPATOTOXICITY FOLLOWING NEVIRAPINE-CONTAINING REGIMENS IN HIV-1-INFECTED INDIVIDUALS. Pharmacological Research. 46(3). 295–300. 36 indexed citations

19.

Wit, Ferdinand W.N.M., Robin Wood, Andrzej Horban, et al.. (2001). Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS. 15(18). 2423–2429. 29 indexed citations

20.

Veldkamp, Agnes I., Marianne Harris, Julio Montaner, et al.. (2001). The Steady‐State Pharmacokinetics of Efavirenz and Nevirapine When Used in Combination in Human Immunodeficiency Virus Type 1–Infected Persons. The Journal of Infectious Diseases. 184(1). 37–42. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact